A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here

Thursday 26 June 2008

The Angiomax bill -- does it stand a chance?

According to analyst Andrew Parmentier (Friedman, Billings Ramsey, left), the odds on the Angiomax patent term extension bill passing successfully through all its legislative stages are "still less than 50 per cent". The bill may have had a smooth passage through the House of Representatives but it still has to make it through the Senate and win the signature of the President. "We advise investors not to blindly interpret this event in the House as patent relief for Angiomax," said Parmentier in a note to investors: "we continue to see road-blocks in the Senate" [Source: CNNMonet.com].

No comments: